Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Repligen Corporation    RGEN

REPLIGEN CORPORATION

(RGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen: 2Q Earnings Snapshot

07/30/2020 | 08:13am EDT

WALTHAM, Mass. (AP) _ Repligen Corp. (RGEN) on Thursday reported second-quarter profit of $15.9 million.

The Waltham, Massachusetts-based company said it had profit of 30 cents per share. Earnings, adjusted for one-time gains and costs, came to 42 cents per share.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 28 cents per share.

The drug developer posted revenue of $87.5 million in the period, also beating Street forecasts. Six analysts surveyed by Zacks expected $78.1 million.

Repligen expects full-year earnings in the range of $1.24 to $1.29 per share, with revenue in the range of $332 million to $340 million.

Repligen shares have climbed 50% since the beginning of the year. The stock has increased 47% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGEN at https://www.zacks.com/ap/RGEN

© 2020 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about REPLIGEN CORPORATION
06:36aREPLIGEN  : HC Wainwright Adjusts Repligen's Price Target to $225 From $168, Mai..
MT
03/18INSIDER TRENDS : Insider Sales Continue 90-Day Trend at Repligen
MT
03/17Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor ..
GL
03/15REPLIGEN  : RGEN) Insider Makes Significant Share Sale
MT
03/12INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at Repligen
MT
03/03Repligen Corporation to Present at Barclays Global Healthcare Conference
GL
02/25REPLIGEN  : SVB Leerink Adjusts Repligen's Price Target to $250 From $220, Keeps..
MT
02/24REPLIGEN  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
02/24REPLIGEN  : Reports Growth in Q4 Adjusted Earnings, Revenue; Issues 2021 Targets
MT
02/24REPLIGEN : 4Q Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2021 513 M - -
Net income 2021 76,8 M - -
Net cash 2021 322 M - -
P/E ratio 2021 154x
Yield 2021 -
Capitalization 11 339 M 11 339 M -
EV / Sales 2021 21,5x
EV / Sales 2022 18,1x
Nbr of Employees -
Free-Float 91,9%
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 238,86 $
Last Close Price 207,02 $
Spread / Highest target 21,2%
Spread / Average Target 15,4%
Spread / Lowest Target -3,39%
EPS Revisions
Managers and Directors
NameTitle
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
Jim Bylund Senior Vice President-Global Operations & IT
Sector and Competitors
1st jan.Capitalization (M$)
REPLIGEN CORPORATION8.03%11 288
ABBOTT LABORATORIES10.42%214 178
MEDTRONIC PLC4.15%164 465
BECTON, DICKINSON AND COMPANY-0.92%72 039
ALIGN TECHNOLOGY, INC.10.89%46 893
HOYA CORPORATION-3.71%45 739